Alpha1-Adrenergic Receptor Activation Stimulates Calcium Entry and Proliferation via TRPC6 Channels in Cultured Human Mesangial Cells

Fanwu Kong a  Linlin Ma a  Li Zou a  Kexin Meng a  Tianrong Ji a  Lei Zhang a  Rui Zhang a  Jundong Jiao a,b

a Department of Nephrology, The Second Affiliated Hospital, Harbin Medical University, b Institute of Nephrology, Harbin Medical University, Harbin, China

Key Words
TRPC6 • Mesangial cells • Adrenoceptor • ERK signaling

Abstract

**Background and Aims:** There is accumulating evidence that sympathetic nervous hyperactivity contributes to the pathogenesis of glomerular sclerosis independent of blood pressure effects. A previous study showed that α1-adrenoceptor (α1-AR) antagonists inhibit mesangial cell (MC) proliferation. However, the underlying mechanism remains unclear. **Methods and Results:** We found that α1-AR is expressed in a human mesangial cell line. The α1-AR agonist phenylephrine (PE) induced Ca2+ influx as well as release from intracellular Ca2+ stores. Blockade of TRPC6 with siRNA, anti-TRPC6 antibodies and a TRPC blocker attenuated the PE-induced [Ca2+]i increase. Additionally, the PE-induced [Ca2+]i increase was phospholipase C dependent. Furthermore, PE induced a [Ca2+]i increase even when the intracellular Ca2+ stores were already depleted. This effect was mimicked by an analog of diacylglycerol. These results suggested that, upon α1-AR stimulation, TRPC6 mediates Ca2+ influx via a receptor-operated Ca2+ entry mechanism. Finally, TRPC6 contributes to the PE-induced MC proliferation. The mechanisms are associated with the extracellular signal-regulated kinase (ERK) signaling pathway because blockade of TRPC6 and chelation of extracellular Ca2+ abrogated PE-induced ERK1/2 phosphorylation. **Conclusion:** TRPC6 channels are involved in α1-AR activation-induced Ca2+ entry, which mediates proliferation via ERK signaling in human MCs.

F. Kong and L. Ma contributed equally to this work.

Jundong Jiao  Xuefu Road 246, Harbin 150081, Heilongjiang Province (P. R. China)  Tel. 86-451-86605328, Fax 86-451-86605328, E-Mail jiaojundong@163.com
Introduction

There is convincing evidence that the hyperactivity of the sympathetic nervous system is a hallmark of chronic kidney disease (CKD) [1]. The increased sympathetic activity contributes to the progression of CKD and to the pathogenesis of hypertension. Several studies have shown that the inhibition of sympathetic excitation, either by renal denervation or pharmacologic agents, attenuates renal damage independent of blood pressure effects in animal models of CKD [2-5]. The role of renal sympathetic nerves has important clinical implications, and percutaneous catheter-based renal denervation has recently become available to disrupt renal sympathetic nerves. However, the precise role of sympathetic nervous system activation in the pathogenesis of glomerulosclerosis is poorly understood.

Mesangial cell (MC) proliferation and extracellular matrix expansion play a pivotal role in the pathogenesis of glomerulosclerosis. A variety of signaling molecules are involved in proliferation and extracellular matrix expansion of MCs [6-9]. However, there have been relatively few studies to investigate the role of sympathetic hyperactivity in MCs.

A previous study showed that doxazosin, prazosin and dicentrine, all of which are α₁-adrenoceptor (α₁-AR) antagonists, cause a dose-dependent inhibition of the mesangial cell growth induced by serum and platelet-derived growth factor (PDGF) [10]. Furthermore, the α₁-AR antagonist doxazosin reduces mesangial cell matrix production [11]. However, the underlying mechanisms remain poorly defined. The gene expression of all three α₁-AR subtypes (α₁A, α₁B, and α₁D) was identified in the kidney cortex [11, 12]. Using in situ hybridization, α₁-AR mRNA staining was detected in glomerular MCs [12]. Prototypically, stimulation of α₁-AR leads to the activation of G protein-coupled phospholipase Cβ (PLCβ), which catalyzes the formation of inositol 1,4,5-triphosphate (IP₃) and diacylglycerol (DAG), thereby causing a release of internal Ca²⁺ stores and an accompanying sustained Ca²⁺ influx [13, 14]. In many cases, transient receptor potential canonical (TRPC) channels are thought to contribute to the sustained Ca²⁺ influx through store-operated Ca²⁺ entry (SOCE) or receptor-operated Ca²⁺ entry (ROCE) [15-20].

Our previous studies demonstrated that TRPC6 is an important pathway of Ca²⁺ influx and is involved in mesangial cell proliferation and Ca²⁺ entry induced by hypoxia and calcium-sensing receptors [21, 22]. We therefore sought to investigate whether α₁-AR activation stimulates Ca²⁺ influx and proliferation via TRPC6 in human MCs and, if so, to identify the underlying mechanisms.

Materials and Methods

Cell culture and plasmid transfection

An established, stable, human mesangial cell line was cultured as previously described [21]. Briefly, the cells were cultured in RPMI1640 medium (HyClone, USA) supplemented with 10% fetal bovine serum (HyClone, USA) in 5% CO₂ at 37°C. Human MCs between passages 3 and 15 were used. Human MCs were transiently transfected with TRPC6 siRNA or scrambled siRNA (Santa Cruz, USA) using the Xtreme GENE siRNA transfection reagent (Roche, Germany) according to the manufacturer’s instructions. Cells were used for experiments 48-72 h after transfection.

Reverse transcription PCR

Reverse transcription was performed using standard methods. The specific primer sequences used to amplify α₁A-AR, α₁B-AR and α₁D-AR were as follows (5'-3'): α₁A-AR Sense: TGA TTT CAA GCC CTC TGA AAC AG; α₁A-AR Antisense: ATG TCC TTG TGT TGC CCT TCC AC; α₁B-AR Sense: CTT CAC CTT CAA GCT CCT GAC CGA G; α₁B-AR Antisense: TGC CAG AAA AGC AGCTGC CCC TCT C; α₁D-AR Sense: TGT CGC ACA AGA TCG CCG CC; α₁D-AR Antisense: CCA GCA CAC TCC GCG GCC TA.

Western Blotting

Western blots were performed using a standard protocol. The membrane was probed with the following primary antibodies: polyclonal rabbit anti-TRPC6 antibodies (Abcam, USA), rabbit anti-α₁-AR
antibodies (Abcam, USA), phospho-ERK1/2 or total-ERK1/2 antibody (Cell Signaling) or anti-actin antibody (Santa Cruz, USA). The membranes were washed extensively and incubated with fluorescence-conjugated goat anti-rabbit or goat anti-mouse IgG secondary antibodies (Invitrogen, USA). Western blot bands were quantified using the Odyssey infrared imaging system (LI-COR Bioscience, USA).

**Fluorescence measurement of \([Ca^{2+}]_i\)**

MCs were grown on coverslips and loaded with Pluronic F-127 (0.03%; Sigma, USA) and Fluo-3/AM (0.03%; Sigma) at 37°C for 45 min. Fluorescence changes in the Fluo-3/AM-loaded cells were detected by laser scanning confocal microscopy (FV300; Olympus, Japan). The Ca\(^{2+}\)-free bath solution contained no CaCl\(_2\) and 0.5 mM EGTA. MCs were then stimulated with agonists or inhibitors as described in the results. \([Ca^{2+}]_i\) was expressed as a pseudo-ratio value of the actual fluorescence intensity divided by the average baseline fluorescence intensity. The calcium concentration was calculated using the formula described by Grynkiewicz et al [23]. Calibrations were performed immediately following each experiment. High \([Ca^{2+}]_i\) conditions were achieved by adding 4 μM ionomycin, and low \([Ca^{2+}]_i\) conditions were achieved by adding 10 mM EGTA. Data from 20 to 40 cells were summarized in a single run, and at least three independent experiments were conducted.

**Cell proliferation assay**

Cell proliferation was measured using a Cell Proliferation ELISA BrdU kit (Roche, Germany) according to the manufacturer’s protocol. Cells were seeded in a 96-well plate (5000 cells/well) and cultured for 24 h. After starvation for another 12 h in serum-free medium, cells were incubated in the same medium supplemented with different treatments for 24 h. Six hours before the end of incubation, BrdU was added to the medium, and the cells were incubated for 6 h. The absorbance at 450 nm (reference wavelength: 630 nm) was measured with a scanning multi-well spectrophotometer (Amersham Pharmacia Biotech). The absorbance values correlated directly with the amount of DNA synthesis and therefore with the number of proliferating cells in culture. Stimulation was expressed as the fold proliferation over the basal growth of the control set as unity.

**Statistical analysis**

Data are presented as the mean ± SEM with the number (n) of experiments indicated. Statistical analyses were performed using an unpaired t-test (SPSS16.0), and graphs were prepared with Adobe Photoshop or were plotted in GraphPad Prism 5 (GraphPad Software, Inc.). A P-value less than 0.05 was considered to be statistically significant.

**Results**

\(\alpha_{1}\)-AR is expressed in human mesangial cells.

We first sought to examine whether \(\alpha_{1}\)-AR is expressed in the human mesangial cell line used in this study. RT-PCR experiments revealed that \(\alpha_{1A}\)-AR mRNA (275 bp) and \(\alpha_{1D}\)-AR mRNA (202 bp) were not detected in cultured human MCs, although they were detected in mouse kidney tissues (data not shown). \(\alpha_{1B}\)-AR mRNA (151 bp) was detected in cultured human MCs and mouse kidney tissues (data not shown), a result that was consistent with previous studies [11, 24]. Experiments without reverse transcriptase confirmed that the PCR products originated from mRNA and not from genomic DNA. Western blot analysis showed a 60 kDa band corresponding to \(\alpha_{1}\)-AR in human MCs and the positive control of mouse kidney tissues (Fig. 1). Taken together, these data indicate that \(\alpha_{1}\)-AR is present in cultured human MCs.

**Fig. 1.** Expression of \(\alpha_{1}\)-AR protein in a human mesangial cell line. Western blotting showed that \(\alpha_{1}\)-AR protein expression, as a 60 kDa band, was found in both the cultured human MCs and the positive control of mouse kidney tissues (MK).
Kong et al.: α₁-Adrenergic Receptor Activation Stimulates Calcium Entry in Mesangial Cells

α₁-AR agonists stimulate an [Ca²⁺]ᵢ increase in human MCs.

The effect of α₁-AR agonists on the [Ca²⁺]ᵢ in human MCs was assessed using Fluo-3/AM assays. As shown in Fig. 2A and 2B, the presence of 1.8 mM extracellular Ca²⁺ and 10 μM phenylephrine (PE), a known α₁-AR agonist, evoked a rapid increase in [Ca²⁺]ᵢ and a subsequent sustained increase in [Ca²⁺]ᵢ. MCs exhibited no spontaneous [Ca²⁺]ᵢ changes during these experiments (data not shown). The PE-induced [Ca²⁺]ᵢ increase occurred in a concentration-dependent manner, as shown in Fig. 2C. Pretreatment of MCs with 200 nM prazosin, a selective α₁-AR antagonist, significantly inhibited the PE-induced [Ca²⁺]ᵢ increase (Fig. 2D), indicating that the PE-induced [Ca²⁺]ᵢ elevation is specific for α₁-AR. To examine whether Ca²⁺ influx is involved in the PE-induced [Ca²⁺]ᵢ increase, MCs were stimulated by PE in the absence of extracellular Ca²⁺. As shown in Fig. 2E, PE induced a transient increase in [Ca²⁺]ᵢ in the Ca²⁺-free solutions, which was due to the Ca²⁺ release from intracellular Ca²⁺ stores through α₁-AR activation by PE. However, it is not likely that there is residual Ca²⁺ in the medium because under our experimental conditions, the medium contained no Ca²⁺ and 0.5 mM EGTA was added to chelate the possible trace amounts of Ca²⁺. These data suggest that α₁-AR activation induces Ca²⁺ release from intracellular Ca²⁺ stores. However, the PE-

Fig. 2. Activation of α₁-AR induces an increase in [Ca²⁺]ᵢ in human MCs. The representative image (A) and trace (B) showing that PE induced a [Ca²⁺]ᵢ increase in the presence of 1.8 mM extracellular Ca²⁺. (C) PE induced a [Ca²⁺]ᵢ increase in a concentration-dependent manner. The average [Ca²⁺]ᵢ responses to PE are shown as the means ± SEM (n=3). (D) The representative trace showing that the PE-mediated [Ca²⁺]ᵢ increase was prevented by pretreatment with prazosin. (E) The representative traces of the effect of PE on [Ca²⁺]ᵢ in Ca²⁺-free solution. The results were from at least three independent experiments, and each experiment measured 20 to 40 cells.
TRPC6 is involved in the α₁-AR agonist-induced [Ca²⁺]ᵢ increase. (A) The representative trace showing that pretreatment for 30 min with SKF96365, a TRPC channel blocker, inhibited the PE-induced [Ca²⁺]ᵢ increase. (B) The representative trace showing that pretreatment for 30 min with SN-6, a specific inhibitor of Na⁺/Ca²⁺ exchangers, or efonidipine, a voltage-gated calcium channel blocker, had no apparent effect on the PE-induced [Ca²⁺]ᵢ increase. (C) Western blot experiments showing that transfection with TRPC6 siRNA significantly reduced TRPC6 protein expression compared with transfection with scrambled siRNA (Scr). Data are shown as the means ± SEMs (***p<0.001 vs Scr group; n=3). (D) The representative trace showing that transfection with TRPC6 siRNA significantly reduced the PE-induced [Ca²⁺]ᵢ increase. (E) Summary of data showing that pretreatment with anti-TRPC6 antibody (0, 1, 4, or 10 μg/ml) produced a concentration-dependent inhibition of the PE-induced [Ca²⁺]ᵢ increase. Data are shown as the means±SEM (*p<0.05, ***p<0.001 vs 0 µg/ml anti-TRPC6 antibody group; n=3). The results were from at least three independent experiments, and each experiment measured 20 to 40 cells.

TRPC6 is required for the α₁-AR agonist-induced [Ca²⁺]ᵢ increase.

Because TRPC channels, voltage-gated calcium channels and Na⁺/Ca²⁺ exchangers are the main pathways for Ca²⁺ influx in MCs, we examined the role of these pathways in the PE-induced [Ca²⁺]ᵢ increase. As shown in Fig. 3A and 3B, pretreatment with 30 μM SKF96365, a nonselective TRPC channel blocker, significantly inhibited the PE-induced [Ca²⁺]ᵢ increase. However, pretreatment with 10 μM efonidipine, a voltage-gated calcium channel blocker, or 10 μM SN-6, a specific inhibitor of Na⁺/Ca²⁺ exchangers, had no apparent effect (Fig. 3B). These data suggest that TRPC-dependent Ca²⁺ entry is involved in the PE-induced [Ca²⁺]ᵢ increase. To investigate whether TRPC6 contributes to the PE-induced [Ca²⁺]ᵢ increase, we used siRNA technology to down-regulate TRPC6 expression. As shown in Fig. 3C, the specificity and efficiency of TRPC6-siRNA were confirmed by western blot analyses. Consistent
Kong et al.: α₁-Adrenergic Receptor Activation Stimulates Calcium Entry in Mesangial Cells

PLC and ROCE are involved in the α₁-AR agonist-induced [Ca²⁺]i increase. (A) The representative trace showing that pretreatment for 30 min with U73122, a PLC inhibitor, almost completely abolished the PE-induced [Ca²⁺]i increase. (B) Cells were stimulated with TG for 10 min in Ca²⁺-free solution, and then, 1.8 mM Ca²⁺ was re-added to the solution. The representative trace showed that PE evoked an additional increase in [Ca²⁺]i. (C) The representative trace showing that the PE-induced [Ca²⁺]i increase was inhibited by pretreatment for 30 min with anti-TRPC6 antibodies (5 μg/ml). (D) The representative trace showing that, using the same protocol, OAG induced a similar [Ca²⁺]i increase. (E) The representative trace showing that PE did not produce a subsequent [Ca²⁺]i increase after the application of OAG. The results were from at least three independent experiments, and each experiment measured 20 to 40 cells.

with our previous reports [21, 22], knockdown of TRPC6 did not affect the expression of other isoforms of TRPC6 expressed in human MCs (data not shown). Compared with cells transfected with scrambled siRNA, transfection with TRPC6 siRNA significantly inhibited the PE-induced [Ca²⁺]i increase (p<0.05, n=3; Fig. 3D). Additionally, blockade of TRPC6 with the anti-TRPC6 antibody inhibited the PE-induced [Ca²⁺]i increase in a dose-dependent manner (Fig. 3E). These results strongly demonstrated that TRPC6 is essential for the [Ca²⁺]i increase mediated by α₁-AR activation.

PLC and ROCE are involved in the α₁-AR agonist-induced [Ca²⁺]i increase.

TRPC6 predominantly induces ROCE via PLC signaling pathways upon GPCR activation [25]. Thus, we examined whether the PE-induced [Ca²⁺]i increase is PLC dependent and whether TRPC6 is involved in the PE-induced Ca²⁺ influx via ROCE. As shown in Fig. 4A, pretreatment of cells with U73122 (10 μM), a PLC inhibitor, almost completely abolished the PE-induced [Ca²⁺]i increase, whereas U73343 (10 μM), its inactive analog, had no inhibitory effect (data not shown). To demonstrate that ROCE is involved in the PE-induced Ca²⁺ increase, we used a Ca²⁺ depletion/Ca²⁺ re-addition protocol. The intracellular Ca²⁺ stores were depleted with 1 μM thapsigargin (TG), an endoplasmic reticulum Ca²⁺-ATPase inhibitor, in the absence of extracellular Ca²⁺. Once [Ca²⁺]i had returned to the basal level, extracellular Ca²⁺ was restored to 1.8 mM. As shown in Fig. 4B, the re-addition of extracellular Ca²⁺ initiated an expected [Ca²⁺]i rise, which was due to SOCE, and the subsequent application of PE (10 μM) evoked another [Ca²⁺]i increase, which was regarded as ROCE because, under this condition, the intracellular Ca²⁺ stores were already depleted. The PE-induced Ca²⁺ influx was abolished by pretreatment with TRPC6 antibodies, suggesting that PE-induced Ca²⁺-
Kong et al.: α₁-Adrenergic Receptor Activation Stimulates Calcium Entry in Mesangial Cells

Influx is specific for TRPC6 (Fig. 4C). Using the same protocol, the effect of PE on Ca²⁺ influx was mimicked by the application of OAG (100 μM), a membrane-permeable DAG analog (Fig. 4D). Moreover, PE was added following the application of OAG, and no further [Ca²⁺]i increase was observed (Fig. 4E). These data demonstrate that ROCE via TRPC6 is involved in the Ca²⁺ influx mediated by α₁-AR activation in a PLC-dependent manner.

α₁-AR agonists promote cell proliferation via TRPC6.

Previous studies have shown that α₁-AR activation promotes cell proliferation in many cell types, including MCs [10], and we investigated the contribution of TRPC6 to the α₁-AR agonist-mediated proliferation of MCs. Consistent with previous reports, incubation of cells for 24 h with PE (10 μM) enhanced their proliferation by 22.8% compared with the control group (Fig. 5A, p<0.01; n=3). The cell viability by MTT assessment was not affected under our experimental conditions (data not shown). PE-mediated cell proliferation appeared to act through α₁-AR activation because pretreatment with an α₁-AR selective antagonist, prazosin (200 nM), significantly attenuated PE-mediated cell proliferation (Fig. 5A, p<0.001; n=3). PE-mediated cell proliferation was significantly inhibited by pretreatment with a TRPC channel blocker, SKF96365 (30 μM; Fig. 5A, p<0.001; n=3). Furthermore, transfection of TRPC6 siRNA significantly attenuated the promotion of proliferation by PE compared with scrambled siRNA (Fig. 5B). In the absence of PE, transfection of TRPC6 siRNA or scrambled siRNA did not affect the cell proliferation activity (data not shown). Taken together, these data indicate that TRPC6 contributes to the cell proliferation mediated by α₁-AR activation.

TRPC6 is linked to α₁-AR agonist-mediated cell proliferation via ERK1/2 signaling.

There is evidence that extracellular signal-regulated kinases 1 and 2 (ERK 1/2) contribute to α₁-AR-stimulated mitogenic responses [13, 26, 27]. Recently, ERK signaling has been shown to be regulated downstream of TRPC6 [28-30]. Therefore, we examined whether TRPC6 mediates mesangial cell proliferation via ERK 1/2 in response to α₁-AR stimulation. As shown in Fig. 6A, treatment with PE (10 μM) resulted in time-dependent ERK1/2 phosphorylation, whereas total ERK1/2 was not affected by PE stimulation. The PE-induced ERK1/2 phosphorylation was specific for α₁-AR because this effect was almost completely abolished by the α₁-AR antagonist prazosin (Fig. 6B). The selective ERK1/2 inhibitor PD98059 (100 μM) abolished the ERK1/2 phosphorylation stimulated by PE (Fig. 6C). In parallel, the PE-mediated cell proliferation was attenuated by PD98059 (Fig. 6D), indicating that phosphorylation of ERK1/2 is involved in PE-mediated cell proliferation.
Kong et al.: α₁-Adrenergic Receptor Activation Stimulates Calcium Entry in Mesangial Cells

Recent studies have shown that renal denervation has a blood pressure-independent protective effect against renal injury [2, 5]. Renal sympathetic nerves are involved in unilateral ureter obstruction, a nonhemodynamic model of renal injury [31], suggesting that renal sympathetic denervation may offer protection against renal injury.

**Discussion**

Recent studies have shown that renal denervation has a blood pressure-independent protective effect against renal injury [2, 5]. Renal sympathetic nerves are involved in unilateral ureter obstruction, a nonhemodynamic model of renal injury [31], suggesting that renal sympathetic denervation may offer protection against renal injury.

**Fig. 6.** TRPC6 is linked to α₁-AR agonist-mediated cell proliferation via ERK1/2 signaling. Cells were starved for 12 h and were then treated with 10 µM PE for 10 min with or without pretreatment with various inhibitors for 30 min. The total and phosphorylated ERK1/2 levels were measured by western blot analysis. (A) PE increased ERK1/2 phosphorylation in a time-dependent manner. (B) The PE-induced ERK1/2 phosphorylation was inhibited by 200 nM prazosin (pra). (C) PD98059 (100 µM), a selective ERK1/2 inhibitor, inhibited PE-induced ERK1/2 phosphorylation. (D) PD98059 (100 µM) inhibited PE-induced cell proliferation. (E) SKF96365 (30 µM) or EGTA (100 µM) inhibited PE-induced ERK1/2 phosphorylation. (F) Compared with transfection with scrambled siRNA (Scr), transfection with TRPC6 siRNA attenuated PE-induced ERK1/2 phosphorylation. The results were from at least three independent experiments. Asterisks indicate the statistical significance (**p<0.01 vs PE group; #p<0.05; ##p<0.01 vs control group; ###p<0.001 vs Scr group).
that local nerve-derived signaling molecules contribute to renal injury. However, the underlying mechanisms are poorly understood. Several studies have revealed that the mechanisms may be associated with inflammation [5], oxidative stress [2] and the intrarenal renin-angiotensin system [2, 31]. To date, few studies have investigated the potential effects of renal sympathetic nerves on glomerular MCs. In the present study, we demonstrate that α₁-AR activation induces TRPC6-dependent Ca²⁺ influx, which is involved in the proliferation of human MCs via ERK signaling. This implies that renal sympathetic activation could directly regulate mesangial cell proliferation through neurotransmitters, such as norepinephrine. Other neurotransmitters may also contribute to mesangial cell proliferation. ATP, a co-transmitter of norepinephrine, mediates the proliferation of human MCs [32].

In many cell types, α₁-AR utilizes intracellular Ca²⁺ as a second messenger to modulate cellular function [13, 14]. As with most Gα₁ subclasses, the Ca²⁺ influx by the stimulation of α₁-AR is often mediated by TRPC channels via ROCE or SOCE rather than by voltage-gated Ca²⁺ channels, which may be dependent upon the particular cell type and α₁-AR subtype [13, 14]. Similar to cardiac myocytes [19], vascular smooth muscle cells [33], prostate smooth muscle cells [18], and PC12 cells [20], our results demonstrate that activation of α₁-AR mediates Ca²⁺ influx via TRPC6 in human MCs because the α₁-AR agonist-induced [Ca²⁺]i increase was attenuated by the administration of TRPC6 siRNA, anti-TRPC6 antibodies and TRPC blocker but not by the voltage-gated Ca²⁺ blocker or the inhibitor of Na⁺/Ca²⁺ exchangers. As a receptor-operated channel, TRPC6 can be activated by the DAG produced by activated PLC without involvement of Ca²⁺ stores [25]. We demonstrate that upon stimulation of α₁-AR, TRPC6-mediated Ca²⁺ influx occurs at least via ROCE because the α₁-AR agonist induces a [Ca²⁺]i increase when the intracellular Ca²⁺ stores are already depleted by TG. Moreover, this effect was mimicked by OAG, an analog of DAG, which can directly activate TRPC6 independently of Ca²⁺ store depletion [25]. The concept is supported by recent studies that snapin, a regulator of receptor signaling, augments α₁-AR-induced Ca²⁺ influx through TRPC6 [19, 20]. However, the possibility that other TRPC channels expressed in MCs are also involved in α₁-AR agonist-induced Ca²⁺ influx could not be excluded, given that TRPC6 can form heteromeric channel complexes with other TRPC channels [25].

α₁-AR activates mitogenic responses in various cell types via the mitogen-activated protein kinase (MAPK) family, including ERK, c-Jun N-terminal kinases (JNKs) and p38 kinases [13]. However, the underlying mechanism is not completely clear. Among three canonical MAPK signaling pathways, the ERK pathway plays a central role in regulating cell proliferation in various cell types, including MCs. Indeed, our study showed that α₁-AR stimulation promotes mesangial cell proliferation, a finding that was consistent with that of a previous study [10]. In the present study, we demonstrate that α₁-AR activation-induced proliferation of MCs is associated with ERK1/2 phosphorylation. We found that TRPC6 contributes to ERK signaling because the application of TRPC6 siRNA, the TRPC blocker, or chelation of extracellular Ca²⁺ attenuated α₁-AR activation-induced ERK1/2 phosphorylation. This idea is supported by recently accumulating evidence that TRPC6 induces ERK activation in podocytes [30], neurons [28] and islet cells [29]. In podocytes, enhancement of TRPC6 activity resulted in increased ERK1/2 phosphorylation through a cell-autonomous and a non-cell-autonomous mechanism in a Ca²⁺-dependent manner [30]. In addition, in MCs and HEK293 cells, ERK1/2 may directly activate TRPC6 by phosphorylation at Ser-281 [34]. Thus, the interaction of TRPC6 with ERK1/2 provides positive feedback to Ca²⁺ influx through TRPC6 (Fig. 7). Several other signaling pathways were shown to be regulated downstream
Kong et al.: α₁-Adrenergic Receptor Activation Stimulates Calcium Entry in Mesangial Cells

Cell Physiol Biochem 2015;36:1928-1938
DOI: 10.1159/000430161
Published online: July 17, 2015
© 2015 S. Karger AG, Basel
www.karger.com/cpb

of TRPC6. For example, TRPC6 activates the calcineurin-NFAT (nuclear factor of activated T-cells) and RhoA pathways, both of which are involved in TRPC6-mediated mitogenic responses [25]. Therefore, the possibility that TRPC6 mediates mesangial cell proliferation in response to α₁-AR activation via other signaling pathways could not be excluded and should be further explored.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81441023).

Disclosure Statement

The authors declare that no conflict of interest exists.

References

1. Vink EE, de Jager RL, Blankstijn PJ: Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013;15:95-101.
2. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nakai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A: Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012;125:1402-1413.
3. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Rats JP, Ehmke H, Mall G, Ritz E: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469-1478.
4. Ergüçü M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Sueda T, Noguchi H, Masutani K, Torisu K, Kitazono T: Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int 2015;87:116-127.
5. Vink EE, de Jager RL, Blankstijn PJ: Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013;15:95-101.
6. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nakai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A: Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012;125:1402-1413.
7. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Rats JP, Ehmke H, Mall G, Ritz E: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469-1478.
8. Ergüçü M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Sueda T, Noguchi H, Masutani K, Torisu K, Kitazono T: Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int 2015;87:116-127.
9. Vink EE, de Jager RL, Blankstijn PJ: Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013;15:95-101.
10. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nakai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A: Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012;125:1402-1413.
11. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Rats JP, Ehmke H, Mall G, Ritz E: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469-1478.
12. Papadimitriou A, Peixoto EB, Silva KC, Lopes de Faria JM, Lopes de Faria JR: Inactivation of AMPK mediates high phosphate-induced extracellular matrix accumulation via NOX4/TGFβ-1 signaling in human mesangial cells. Cell Physiol Biochem 2014;34:1260-1272.
13. Pastukhov O, Schwalm S, Romer I, Zangemeister-Wittke U, Pfeilschifter J, Huwiler A: Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts. Cell Physiol Biochem 2014;34:119-133.
14. Xu WF, Guan MP, Zheng ZJ, Gao F, Zeng YM, Qin Y, Xue YM: Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway. Cell Physiol Biochem 2014;34:423-432.
15. Wang JC, Zhao Y, Chen SJ, Long J, Jia QQ, Zhang Q, Chen Y, Long HB: AOPPs induce MCP-1 expression by increasing ROS-mediated activation of the NF-κB pathway in rat mesangial cells: inhibition by sesquiterpene lactones. Cell Physiol Biochem 2013;32:1867-1877.
16. Tsai TJ, Lin RH, Chang CC, Chen YM, Chen CF, Ko FN, Teng CM: Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 1995;70:91-99.
17. Pawluczyn IZ, Patel SR, Harris KP: The role of the alpha-1 adrenoceptor in modulating human mesangial cell matrix production. Nephrol Dial Transplant 2006;21:2417-2424.
18. Kurouga Y, Moriyama N, Nasu K, Kameyama S, Fukasawa R, Yano J, Kawabe K: Distribution of alpha1-adrenoceptor subtype mRNAs in human renal cortex. BJU Int 1999;83:299-304.
19. Zhong H, Minneman KP: Alpha1-adrenoceptor subtypes. Eur J Pharmacol 1999;375:261-276.
20. Hein P, Michel MC: Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal? Biochem Pharmacol 2007;73:1097-1106.
21. Hill AJ, Hinton JM, Cheng H, Gao Z, Bates DO, Hancox JC, Langton PD, James AF: A TRPC-like non-selective

KARGER
cation current activated by alpha 1-adrenoceptors in rat mesenteric artery smooth muscle cells. Cell Calcium 2006;40:29-40.

16. Horinouchi T, Miyake Y, Nishiya T, Nishimoto A, Yorozu S, Jinno A, Kajita E, Miwa S: Characterization of noradrenaline-induced increases in intracellular Ca2+ levels in Chinese hamster ovary cells stably expressing human alpha1A-adrenoceptor. J Pharmacol Sci 2007;105:310-111.

17. Thebault S, Flourakis M, Vanoverbergh E, Vandermeere F, Roudbaraki M, Lehen'kyi V, Slonimanny C, Beck B, Mariot P, Bonnal JL, Mauroy B, Shuba Y, Capiod T, Skryma R, Prevشارska N: Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 2006;66:2038-2047.

18. Thebault S, Zholos A, Enfissi A, Slonimanny C, Dewailly E, Roudbaraki M, Parys J, Prevشارska N: Receptor-operated Ca2+ entry mediated by TRPC3/TRPC6 proteins in rat prostate smooth muscle (PS1) cell line. J Cell Physiol 2005;204:320-328.

19. Mohl MC, Ismaa SE, Xiao XH, Friedrich O, Wagner S, Nikolova-Krstevski V, Wu J, Yu ZY, Feneley M, Fatkin D, Allen DG, Graham RM: Regulation of murine cardiac contractility by activation of alpha(1A)-adrenergic receptor-operated Ca(2+) entry. Cardiovasc Res 2011;91:310-319.

20. Suzuki F, Morishima S, Tanaka T, Muramatsu I: Snapin, a new regulator of receptor signaling, augments alpha1A-adrenoceptor-operated calcium influx through TRPC6. J Biol Chem 2007;282:29563-29573.

21. Liao C, Yang H, Zhang R, Sun H, Zhao B, Gao C, Zhu F, Jiao J: The upregulation of TRPC6 contributes to Ca(2+) (+) signaling and actin assembly in human mesangial cells after chronic hypoxia. Biochem Biophys Res Commun 2012;421:750-756.

22. Meng K, Xu J, Zhang C, Zhang R, Yang H, Liao C, Jiao J: Calcium sensing receptor modulates extracellular calcium entry and proliferation via TRPC3/6 channels in cultured human mesangial cells. PLoS One 2014;9:e89777.

23. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.

24. Bucher M, Kees E, Taeger K, Kurtz A: Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia. Crit Care Med 2003;31:566-571.

25. Dietrich A, Gundermann T: TRPC6: physiological function and pathophysiological relevance. Handb Exp Pharmacol 2014;222:157-188.

26. Cipolletta E, Monaco S, Maione AS, Vitiello L, Campiglia P, Pastore L, Franchini C, Novellino E, Limongelli V, Bayer KU, Means AR, Rossi G, Iaccarino G, Illario M: Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology 2010;151:2747-2759.

27. Cotecchia S: The alpha1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct Res 2010;30:410-419.

28. Yao H, Peng F, Fan Y, Zhu X, Hu G, Buch SJ: TRPC channel-mediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway. Cell Death Differ 2009;16:1681-1693.

29. Hayes HL, Moss LG, Schisler JC, Haldeman JM, Zhang Z, Rosenberg PB, Newgard CB, Hohmeier HE: Pdx-1 activates islet alpha- and beta-cell proliferation via a mechanism regulated by transient receptor potential cation channels 3 and 6 and extracellular signal-regulated kinases 1 and 2. Mol Cell Biol 2013;33:4017-4029.

30. Chiluizza D, Krishna S, Schumacher VA, Schondonff J: Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2). J Biol Chem 2013;288:18407-18420.

31. Kim J, Padanilam BJ: Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 2013;24:229-242.

32. Vonend O, Grote T, Oberhauser V, Von K, I, Rump LC: P2Y-receptors stimulating the proliferation of human mesangial cells through the MAPK42/44 pathway. Br J Pharmacol 2003;139:1119-1126.

33. Inoue R, Okada T, Onoue H, Hara Y, Shimizu S, Naitho S, Ito Y, Mori Y: The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. Circ Res 2001;88:325-332.

34. Shen B, Kwan HY, Ma X, Wong CO, Du J, Huang Y, Yao X: cAMP activates TRPC6 channels via the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB)-mitogen-activated protein kinase kinase (MEK)-ERK1/2 signaling pathway. J Biol Chem 2011;286:19439-19445.